Ibrutinib Monotherapy in Relapsed or Refractory, Transformed Diffuse Large B-cell Lymphoma

Area of Science:

• Hematology
• Oncology
• Clinical Trials

Background:

• Histologic transformation to diffuse large B-cell lymphoma (tDLBCL) is common in indolent lymphomas.
• Management of relapsed or refractory (R/R) tDLBCL often lacks novel therapeutic options.
• Few studies evaluate novel agents for R/R tDLBCL.

Purpose of the Study:

• To prospectively evaluate the efficacy and safety of ibrutinib monotherapy in patients with R/R tDLBCL.
• To determine the overall response rate (ORR) as the primary endpoint.

Main Methods:

• A single-arm, prospective study.
• Twenty patients with pathologically documented R/R tDLBCL were enrolled.
• Patients received ibrutinib monotherapy.

Main Results:

• The ORR was 35%, with 15% complete responses.
• Median progression-free survival was 4.1 months; median overall survival was 22.4 months.
• Disease control was observed in 75% of patients beyond 2 months and 15% beyond 1 year.

Conclusions:

• Ibrutinib demonstrated low toxicity and meaningful efficacy in R/R tDLBCL.
• Ibrutinib provided short-term disease control in most patients.
• Results suggest ibrutinib's potential utility as a bridge to definitive treatment.